Validation of the Kansas City Cardiomyopathy Questionnaire in Patients with Tricuspid Regurgitation: The Tri-QOL Study
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Importance Improving patients’ health status is a key goal of treating tricuspid regurgitation (TR). The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart-failure disease specific health status measure that has been used to capture the health status impact of TR and the benefit of transcatheter tricuspid valve intervention (TTVI), but its validity in this clinical setting is unknown. Objective To evaluate the psychometric properties of the KCCQ in patients with TR. Design, Setting, Participants Data were pooled from patients with severe TR enrolled in 11 manufacturer-sponsored trials of TTVI. The data were transferred to the FDA to harmonize and anonymize prior to analysis by an independent center. Prespecified analyses included evaluation of internal consistency, reproducibility, responsiveness, construct validity, and prognostic validity. Results The study cohort comprised 2693 patients (mean age 79±8 years, 62% women, mean baseline KCCQ Overall Summary [KCCQ-OS] score 50±23), enrolled in either single-arm (n=1517) or randomized (n=1176) investigations of TTVI. There was strong internal consistency within individual domains (Cronbach’s alpha 0.77-0.83). Among clinically stable patients between 1 and 6 months, there were small mean changes in KCCQ domain and summary scores (differences of -0.1 to 1.9 points), demonstrating reproducibility. In contrast, domain and summary scores of patients who underwent TTVI showed large improvements at 1-month after treatment (mean changes 12.1-21.4 points), indicating excellent responsiveness. Construct validity was moderately-strong to strong when the domains were compared with best available reference measures (Spearman correlations 0.47-0.69). The KCCQ-OS was strongly associated with clinical events, with lower scores being associated with an increased risk of mortality (HR 1.34 per 10-point decrement, 95% CI 1.22-1.47) and heart failure hospitalization (HR 1.24 per 10-point decrement, 95% CI 1.17-1.31). Conclusions and Relevance The KCCQ has strong psychometric properties, including reliability, responsiveness, and validity in patients with severe TR. These data support its use in clinical investigations of TTVI as a measure of the impact of treatment on patients’ symptoms, function, and quality of life. KEY POINTS Question Is the Kansas City Cardiomyopathy Questionnaire (KCCQ) a valid disease-specific health status measure in patients with severe tricuspid regurgitation (TR)? Findings Data on 2693 patients from 11 clinical trials of various transcatheter tricuspid valve interventions (TTVI) from 2 device manufacturers were pooled and then analyzed by an academic analytic center. We found that the KCCQ has strong psychometric properties, including reliability, responsiveness, and validity in patients with severe TR. Meaning These data support continued use of the KCCQ in clinical trials of TTVI as a measure of the impact of treatment on patients’ symptoms, function, and quality of life.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Validation of the Kansas City Cardiomyopathy Questionnaire in Patients with Tricuspid Regurgitation: The Tri-QOL Study
- Date Crossref
- 08/02/2024
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Saint Luke's Health System pays non établi dans la noticeÉtablissement de santé
-
Saint Luke's Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Missouri–Kansas City pays non établi dans la noticeUniversité ou école supérieure
-
Mayo Clinic in Arizona pays non établi dans la noticeÉtablissement de santé
-
United States Food and Drug Administration pays non établi dans la noticeOrganisme public
-
Cardiovascular Research Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
St. Francis Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute pays non établi dans la noticeUniversité ou école supérieure
-
US Food and Drug Administration pays non établi dans la noticeInstitution
Saint Luke's Health System, Saint Luke's Hospital et University of Missouri–Kansas City, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.